

[ADD TRANSLATION IN LOCA	L LANGU	IAGE] / PATIENT INFOR	MATION				
[LOCAL LANGUAGE] / FIRST NAME			[LOCAL LANGUAGE] / TELEPHONE NUMBER		R [LOCAL LAN	[LOCAL LANGUAGE] / E-MAIL ADDRESS	
[LOCAL LANGUAGE] / LAST NAME			[LOCAL LANGUAGE] / ADDRESS				
[LOCAL LANGUAGE] / DATE OF BIRTH (DD/MM/YYYY)		[LOCAL LANGUAGE] / ID	[LOCAL LANGUAGE] /	ANGUAGE] / [LOCAL LANGU POST CODE		[LOCAL LANGUAGE] / COUNTRY	
ADD TRANSLATION IN LOCA	L LANGU	IAGE] / REFERRAL INFO	RMATION				
[LOCAL LANGUAGE] / CLINIC NAME	[LOCAL LA	NGUAGE] / CLINIC ID	[LOCAL LANGUAGE] / TELEF	PHONE NUMB	BER [LOCAL LANGUAGE] / E-MAIL ADDRESS		
[LOCAL LANGUAGE] / REFERRING CLINICIAN			[LOCAL LANGUAGE] / ADDRESS				
[LOCAL LANGUAGE] / FAX		[LOCAL LANGUAGE] / CITY	[LOCAL LA	NGUAGE] /	[LOCAL LANGUAGE] / COUNTRY]		
VERACITY PLUS: TRISOMIES 13, 18, 21; VERACITY PREMI			WIN PREGNANCIES TRISOMIES 13, 18, 21 UM: TRISOMIES 13, 18, 21 S (del22q11.2, del1p36,	;	[ADD LOCAL LANGUAGE] / TEST INDICATIONS Tick appropriate box & add comments [ADD LOCAL LANGUAGE] / PRIOR PREGNANCY RISK [ADD LOCAL LANGUAGE] / ABNORMAL ULTRASOUND [ADD LOCAL LANGUAGE] / ADVANCED MATERNAL AGE [ADD LOCAL LANGUAGE] / SERUM SCREEN RISK [ADD LOCAL LANGUAGE] /		
DD LOCAL LANGUAGE] / [LOCAL LANGUAGE] / [LOCAL LANGUAGE] / NO			after the 12+0 week of pregnancy post conception (in accordance with GenDG).		RISK SCORE: 1IN DD LOCAL LANGUAGE] /		
[ADD LOCAL LANGUAGE] / CLINICAL INFORMATION Complete all sections below [ADD LOCAL LANGUAGE] / MATERNAL INFORMATION [ADD LOCAL LANGUAGE] / MATERNAL INFORMATION REDRAW TEST:			GUAGE] / TEST INFORMATION JAGE] / [LOCAL] / [LOC	N L	RISK SCORE: 1IN DD LOCAL LANG RISK SCORE: 1IN	UAGE] /	
SESTATIONAL AGE (WEEK + DÂY) WEIGHT (KG		HEIGHT (CM)	[ADD LOCAL LANGUAGE] / COLLECTION DATE (DD/MM/YY):		[ADD LOCAL LANGUAGE] / FAMILY HISTORY [ADD LOCAL LANGUAGE] / OTHER		
[ADD LOCAL LANGUAGE] / NUMBER O [ADD LOCAL LANGUAGE] / 1 FETUS - 1 [ADD LOCAL LANGUAGE] / 1 FETUS - 1 [ADD LOCAL LANGUAGE] / 2 FETUSES MONOCHORIONIC TWIN [ADD LOCAL LANGUAGE] / 2 FETUSES DIO [ADD	/ANISHED TWI	IVF PREGNANCY: [LOCAL LANGUAGE] / [[IF IVF, EGG USED: [LOCAL LANGUAGE] / [[[LOCAL] / [LOCAL] / [ADD LOT LANGUAY AGE AT EGG [LOCAL] / [LOCAL] / [LOCAL] / [LOCAL] / [LOCAL] / NO	CAL '	DD LOCAL LANG	UAGE] / CLINICIAN COMMENTS	
PATIENT CONSENT							
By placing my signature signing below 1. Declare that I have had the opportunity to form including the benefits, risks and limits 2. Authorize my referring clinician to col	receive coun tions of the \	/ERACITY test, as well as the rea	asons for performing the test an	d availability	of alternative test	ing options to my satisfaction	

- Authorize my referring clinician to collect the necessary blood samples, and to submit this form and transport the samples to MVZ Martinsried GmbH laboratories for the purposes of conducting the tests requested with this form.
- 3. Authorize MVZ Martinsried GmbH to use any part of or the entirety of the blood sample for the purposes of conducting the tests requested with this form.
- 4. Authorize MVZ Martinsried GmbH to communicate the results of the test to my referring clinician.
- 5. Confirm that all the information on this form is true to the best of my knowledge.

Your test results and any unused biological material can help MVZ Martinsried GmbH improve and further develop the quality, accuracy and effectiveness of diagnosis and help us expand the scope of genetic testing. For this reason, MVZ Martinsried GmbH would like to use your anonymized, de-identified (i.e. after removing all the personal information from which you can be identified) test results and unused biological material.

 $\label{eq:local_problem} \square \ \text{For the above scope, I consent to the inclusion of my test results in MVZ Martinsried GmbH database, the coding, storing and using of biological material and the coding of the cod$

[ADD LOCAL LANGUAGE] / DATE

CLINICIAN ATTESTATION

I hereby certify and undertake that:

- 1. The patient has been informed that the test will only test for the disorder(s) requested with on this form and has been duly and thoroughly counseled about the test and has received all the advice necessary to provide their informed consent, including the benefits, risks, and limitations of the VERACITY test.
- 2. I have answered all the patient's queries about the VERACITY test.
- 3. This form has been completed according to the wishes and instructions of the patients.
- 4. I have obtained the patient's informed consent and have attested their signature.

[ADD LOCAL LANGUAGE] / CLINICIAN SIGNATURE

[ADD LOCAL LANGUAGE] / DATE





INFORMATION FOR PATIENTS

INFORMATION FOR PATIENTS				
[ADD TRANSLATION IN LOCAL LANGUAGE] / PATIENT INFOR	MATION			
[ADD TRANSLATION IN LOCAL LANGUAGE] / FIRST NAME	[ADD TRANSLATION IN LOCAL LANGUAGE] / GENDER (MALE/FEMALE/OTHER - SPECIFY KARYOTYPE)			
[ADD TRANSLATION IN LOCAL LANGUAGE] / LAST NAME	[ADD TRANSLATION IN LOCAL LANGUAGE] / TELEPHONE NUMBER (COUNTRY CODE & NUMBER)			
[ADD TRANSLATION IN LOCAL LANGUAGE] / DATE OF BIRTH (DD/MM/YYYY)	[ADD TRANSLATION IN LOCAL LANGUAGE] / E-MAIL ADDRESS			
I understand that I will be tested for:				
VERACITY TEST : VERACITY is a Non-Invasive Prenatal Test (NIPT) which can be taken by pregnant women during or after the 10th week of pregnancy to screen for certain genetic conditions in the developing fetus before birth. VERACITY tests for the presence of an extra chromosome – a genetic condition called trisomy – in chromosomes 13, 18 and 21. VERACITY also offers additional testing for changes in the number of X and Y chromosomes (sex chromosome aneuploidies), and sub-chromosomal deletions (loss of a part of a chromosome). VERACITY can also provide fetal sex information, if you opt to know.	INTERPRETING NIPT RESULTS: The healthcare provider ordering this test is responsible to understand the specific uses and limitations of the test, communicate this information to you and answer any questions you may have. VERACITY only tests and reports on the tests selected on the information form. The VERACITY test does not test for other conditions such as triploidy (3 copies of all chromosomes), mosaicism (some cells having the normal number of chromosomes and others having an abnormal number), partial trisomy, or translocation (wrong rearrangement of chromosomes). The test will not identify all deletions associated with each microdeletion syndrome. A negative result is reported as VERY LOW RISK for the specific condition and indicates that the possibility of the fetus			
SAMPLE COLLECTION : Your healthcare provider will take a blood sample from your arm, following standard phlebotomy practices, and send it to MVZ Martinsried GmbH laboratories for analysis. The blood draw does not pose any serious physical harm to you or the fetus. Additional sample may be needed if there is a shipping delay, breakage of the sample collection tubes, sample degradation or contamination, or if the sample has been submitted incorrectly.	having that condition is very low. A positive result is reported as VERY HIGH RISK for the specific condition and indicates that there is an increased possibility of the fetus having the specified condition. A VERY HIGH RISK result in twin pregnancies indicates very high risk of at least one fetus having the specified condition. The result of this test does not eliminate the possibility that other genetic conditions might be present, nor does it guarantee a healthy baby. As VERACITY is a screening test, a positive result should always be confirmed with a diagnostic test such as amniocentesis. Results, possible next steps and clinical management should always be considered in the context of other clinical criteria and should be fully discussed with your healthcare provider.			
TESTING PROCESS : Genetic material (DNA) from the developing fetus's placenta is present in the pregnant woman's blood. With the help of specialized equipment and software, VERACITY uses an innovative, patented technology called 'Target Capture Enrichment Technology' to isolate the fetal DNA, and calculate whether there is an increased risk of the fetus having an aneuploidy or a microdeletion. If the quantity of the fetus's DNA (cffDNA) in the blood sample is too low for accurate analysis, redraw samples will be requested. Although rare, there is always a chance that a result will not be obtained due to lack of genetic material.	 ELIGIBILITY CRITERIA: Singleton or twin pregnancies are eligible after 10th week of gestation. Twin pregnancies in which loss of 1 fetus occurred (vanished twin) are eligible for testing after the 10th week of gestation and 4 weeks after the vanishing event. Patients with malignancies or history of malignancies, with bone marrow or organ transplant, or with recent transfusion, are not eligible for the test. Twin or vanished twin IVF pregnancies conceived using a donor egg are not eligible for the test. Twin pregnancies and vanished twin pregnancies are not eligible for testing for sex chromosome aneuploidies. 			
By my signature, I hereby certify that: 1. I have been informed of the nature and purpose of the genetic test. 2. I have been informed of the benefits and limitations of the genetic test by	Completed by: Patient FIRST NAME LAST NAME DATE OF COMPLETION			
3. I have received clear answers to my questions in relation to the genetic test.4. I have received a copy of this form.5. I agree to provide a sample for the above mentioned genetic test.	[ADD LOCAL LANGUAGE] / SIGNATURE			

FIRST NAME

Name of the ordering physician

LAST NAME

I have explained the risks and benefits of the test as well as alternative test methods to the patient. I have answered all the questions from the patient.

[ADD LOCAL LANGUAGE] / DATE OF SIGNATURE

[ADD LOCAL LANGUAGE] / SIGNATURE OF THE ORDERING PHYSICIAN